-+ 0.00%
-+ 0.00%
-+ 0.00%
Leads Biolabs says FDA grants Fast Track status to opamtistomig for first-line biliary tract cancer
Share
Listen to the news
Leads Biolabs says FDA grants Fast Track status to opamtistomig for first-line biliary tract cancer
  • FDA granted Fast Track designation to Leads Biolabs’ opamtistomig (LBL-024) for first-line advanced or metastatic biliary tract cancer.
  • Agency recommended starting talks on a U.S. registration strategy for opamtistomig combined with chemotherapy in biliary tract cancer.
  • Designation followed a prior Fast Track for opamtistomig in extrapulmonary neuroendocrine carcinoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610112147PRIMZONEFULLFEED9843623) on October 12, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending